SODIUM CHLORIDE INHALATION SOLUTION USP 0.9 %
SODIUM CHLORIDE : 0.9 % · DIN 02372215 · SMITHS MEDICAL ASD INC
Health Canada status: CANCELLED POST MARKET
What is SODIUM CHLORIDE INHALATION SOLUTION USP?
SODIUM CHLORIDE INHALATION SOLUTION USP 0.9 % contains SODIUM CHLORIDE : 0.9 %. It is listed in the Health Canada Drug Product Database under DIN 02372215, held by SMITHS MEDICAL ASD INC, supplied as SOLUTION for INHALATION administration. Health Canada currently lists it as cancelled post market, status dated 19-Jul-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02372215 |
|---|---|
| Brand name | SODIUM CHLORIDE INHALATION SOLUTION USP |
| Generic / active ingredient | SODIUM CHLORIDE : 0.9 % |
| Manufacturer | SMITHS MEDICAL ASD INC |
| Strength | 0.9 % |
| Dosage form | SOLUTION |
| Route of administration | INHALATION |
| Schedule | Ethical |
| ATC code | V03AX OTHER THERAPEUTIC PRODUCTS |
| AHFS class | 48:92.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 19-Jul-2016 |
| Original market date | 2012-04-25 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code V03AX OTHER THERAPEUTIC PRODUCTS. 0 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AIRLIFE MODUDOSE 0.9% SODIUM CHLORIDE SOLUTION | 0.9 % | SOLUTION | CARDINAL HEALTH MEDICAL PRODUCTS AND SERVICES | CANCELLED POST MARKET | DIN 01932314 |
| DEHYDRATED ALCOHOL INJECTION | 0.995 ML | LIQUID | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00537640 |
| POTABA CAP 0.5GM | 500 MG | CAPSULE | GLENWOOD INC. | CANCELLED POST MARKET | DIN 00611271 |
| POTABA PWR 2GM/PCK | 2 G | POWDER | GLENWOOD INC. | CANCELLED POST MARKET | DIN 00611298 |
| POTABA TAB 0.5GM | 500 MG | TABLET | GLENWOOD INC. | CANCELLED POST MARKET | DIN 00550175 |
Who else supplies OTHER THERAPEUTIC PRODUCTS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OTHER THERAPEUTIC PRODUCTS appears in 8 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.